Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

16 luglio 2022 Senza categoria
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study
0 out of 5 based on 0 user ratings

Journal of Clinical Oncology, Ahead of Print.

Related Posts

Lascia un commento